Ohio · 2026 legal overview
A careful guide to what federal scheduling, Ohio law, and recent state action mean—and do not mean—for Ohio residents asking about ibogaine.
01 / Federal baseline
The federal starting point is direct: ibogaine is listed as a Schedule I controlled substance. The DEA’s controlled-substances listing identifies ibogaine in Schedule I, the category reserved under federal law for substances with no currently accepted medical use in treatment in the United States and a high potential for abuse.
That status means ibogaine is not an FDA-approved treatment and is not legally available for ordinary treatment in Ohio. It also means that a public conversation about research, policy, or possible future studies should not be mistaken for permission to possess, distribute, prescribe, or provide ibogaine treatment.
For a broader orientation before focusing on legal questions, the Ohio resident guide to ibogaine questions keeps the distinction between interest, evidence, safety, and lawful access in view.
Ohio’s controlled-substances framework includes ibogaine in its Schedule I listing. The state’s statute can be reviewed in the Ohio Revised Code’s Schedule I provisions. Nothing in that listing authorizes private possession or routine treatment use.
Ohio residents may encounter discussions of ibogaine’s possible role in research or policy. Those discussions do not make ibogaine legally available for treatment in Ohio, and they do not replace applicable federal and state restrictions.
02 / Recent state action
Ohio legislative action associated with House Bill 96 established an Ibogaine Treatment Study Committee. In practical terms, a committee can gather information, examine policy questions, and develop findings or recommendations. It does not itself authorize an Ohio clinic, practitioner, or resident to provide, prescribe, possess, or use a Schedule I substance for treatment.
The relevant measure is available through the Ohio Legislature’s House Bill 96 record. Residents should read any future recommendation alongside the actual enacted statutory language and applicable federal law, rather than relying on summaries or promotional claims.
Near Beacon 55’s approach to plain-language information is to separate a proposal, a study process, and a legally available service. That distinction is especially important when the topic involves controlled substances and serious health concerns.
Clear legal thinking begins by distinguishing a policy discussion from authorized research and from treatment availability. They can be related, but they are not interchangeable.
A state committee may study evidence, implementation questions, and possible policy pathways. Its work does not alter the current legal status on its own.
Research involving a Schedule I substance requires specific regulatory and institutional controls. The FDA’s investigational new drug framework describes the pathway used for clinical investigations.
Ibogaine is not legally available for treatment in Ohio. A state study committee or a research discussion is not a pathway to ordinary lawful treatment access.
03 / Resident questions
These answers are general legal context, not legal or medical advice. Individual situations can involve facts and rules that this overview cannot resolve.
A resident may be able to inquire about a lawfully authorized clinical trial if one is recruiting and if the person meets that study’s criteria. Interest in a study is not permission to obtain or use ibogaine outside an authorized research setting.
No. Ibogaine is a Schedule I controlled substance under federal law, and Ohio law also treats it as a controlled substance. The discussion of research or a state study committee does not legalize private possession.
Legitimate research participation is governed by the specific protocol, institutional review process, and applicable federal permissions. It is distinct from ordinary treatment availability in Ohio. For more on uncertainty and health-related claims, see the site’s risk and evidence context.
For a wider map of questions people raise about access, safety, evidence, and lawful alternatives, questions about where ibogaine treatment is available should be approached with the current Ohio and federal limits firmly in mind.